# VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features

> **NCT00117351** · PHASE2 · TERMINATED · sponsor: **Millennium Pharmaceuticals, Inc.**

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Adenocarcinoma, Bronchiolo-Alveolar

## Interventions

- **DRUG:** VELCADE

## Key facts

- **NCT ID:** NCT00117351
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-04
- **Primary completion:** 2007-06
- **Final completion:** 2007-07
- **Target enrollment:** — (—)
- **Why stopped:** insufficient efficacy
- **Last updated:** 2011-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00117351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00117351, "VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00117351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*